Phaseline

Companies › Ensysce Biosciences

Ensysce Biosciences: clinical trials, targets and expected readouts

2 active drug programs in 15 registered trials: 8 Phase 4, 4 Phase 1, 3 Phase 3; Other, Neurology, Infectious disease; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Oxycodone (PF614)
Mu opioid receptor agonist
OPRM1Phase 3Postoperative Pain, Acute; Pharmacokinetics; Laparoscopic Hysterectomy; Liquid Oxycodone …Nov 2026
Nafamostat Mesylate
Serine protease inhibitor
–Phase 1PharmacokineticsDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06690307Oxycodone (PF614)Phase 4Laparoscopic HysterectomyOtherDec 2025
NCT06602271Oxycodone (PF614)Phase 3Postoperative Pain, AcuteNeurologyNov 2026
NCT03054831Oxycodone (PF614)Phase 4Liquid OxycodoneOtherDec 2026
NCT06500793Oxycodone (PF614)Phase 1PharmacokineticsOtherDec 2026
NCT06500793Nafamostat MesylatePhase 1PharmacokineticsOtherDec 2026
NCT07323914Oxycodone (PF614)Phase 3Alzheimer DiseaseNeurologyJan 2027
NCT05722002Oxycodone (PF614)Phase 4SurgeryOtherFeb 2027
NCT07773155Oxycodone (PF614)Phase 4Surgery, Upper ExtremityOtherFeb 2027
NCT02044497Oxycodone (PF614)Phase 4Pediatric Surgical PatientOtherMay 2027
NCT06671002Oxycodone (PF614)Phase 4SurgeryOtherOct 2027
NCT03759028Oxycodone (PF614)Phase 4Supracondylar Humerus FractureOtherDec 2027
NCT06186141Oxycodone (PF614)Phase 4Patient-Controlled AnalgesiaOtherDec 2027
NCT04659317Oxycodone (PF614)Phase 3PainOtherDec 2028
NCT06757140Oxycodone (PF614)Phase 1Drug InteractionsOtherJan 2029
NCT07824258Oxycodone (PF614)Phase 1VasectomyInfectious diseaseDec 2030

From the company's SEC filings

Cash of $1m on 2026-06-30; operating cash outflow about $11m a year; runway about 1 months at that burn, to Jul 2026; 0 of 3 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 2 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

OPRM1 (1)

Companies with the same targets

Inventage Lab. Trevi Therapeutics Shionogi Currax Pharmaceuticals AgelessRx ReacX Pharmaceuticals Akyso Therapeutics Boulder Care Adneuris Therapeutics Alkermes

Companies built like this

Avenue Therapeutics Aligos Therapeutics Atea Pharmaceuticals Shanghai Ark Biopharmaceutical Scholar Rock

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.